HomeCompareACGN vs CL

ACGN vs CL: Dividend Comparison 2026

ACGN yields 519.62% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACGN wins by $82785.60M in total portfolio value
10 years
ACGN
ACGN
● Live price
519.62%
Share price
$0.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$82785.64M
Annual income
$60,051,464,507.48
Full ACGN calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — ACGN vs CL

📍 ACGN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACGNCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACGN + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACGN pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACGN
Annual income on $10K today (after 15% tax)
$44,167.32/yr
After 10yr DRIP, annual income (after tax)
$51,043,744,831.36/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, ACGN beats the other by $51,043,740,239.69/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACGN + CL for your $10,000?

ACGN: 50%CL: 50%
100% CL50/50100% ACGN
Portfolio after 10yr
$41392.84M
Annual income
$30,025,734,954.72/yr
Blended yield
72.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

ACGN
No analyst data
Altman Z
-10.8
Piotroski
3/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACGN buys
0
CL buys
0
No recent congressional trades found for ACGN or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACGNCL
Forward yield519.62%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$82785.64M$40.8K
Annual income after 10y$60,051,464,507.48$5,401.96
Total dividends collected$80827.26M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ACGN vs CL ($10,000, DRIP)

YearACGN PortfolioACGN Income/yrCL PortfolioCL Income/yrGap
1← crossover$62,662$51,961.55$11,012$312.01+$51.6KACGN
2$371,346$304,298.23$12,196$412.95+$359.1KACGN
3$2,082,703$1,685,362.72$13,599$549.66+$2.07MACGN
4$11,062,507$8,834,014.38$15,288$736.64+$11.05MACGN
5$55,690,004$43,853,122.08$17,353$995.28+$55.67MACGN
6$265,907,885$206,319,580.72$19,926$1,357.80+$265.89MACGN
7$1,205,205,519$920,684,081.82$23,194$1,873.82+$1205.18MACGN
8$5,189,499,372$3,899,929,466.64$27,439$2,621.52+$5189.47MACGN
9$21,246,897,259$15,694,132,931.16$33,088$3,727.38+$21246.86MACGN
10$82,785,644,575$60,051,464,507.48$40,806$5,401.96+$82785.60MACGN

ACGN vs CL: Complete Analysis 2026

ACGNStock

Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

Full ACGN Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this ACGN vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACGN vs SCHDACGN vs JEPIACGN vs OACGN vs KOACGN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.